Primary autosomal recessive microcephaly (MCPH, OMIM 251200) is a genetically heterogeneous group of disorders characterized by congenital microcephaly, cognitive impairment and variable epilepsy [
12]. Mutations in
WDR62 are associated with primary microcephaly-2 (MCPH2, OMIM 604317), which is believed to account for 10% of all cases of MCPH [
13]. Clinical features of MCPH2 include epilepsy, marked cognitive impairment, incontinence, sloping forehead and prominent ears. Radiological features are variable and may include polymicrogyria, corpus callosum hypoplasia, heterotopias, pachygyria with cortical thickening, lissencephaly and schizencephaly, although patients can present with isolated microcephaly [
14‐
18]. To date, 34 families have been identified with mutations in
WDR62, the reported affected individuals ranging in age from infancy to mid-teens [
14‐
18].We present here the oldest patients known to have
WDR62 mutations associated with MCPH, providing additional insight into the natural history and phenotypic spectrum of this disorder. It is unclear whether the sudden cardiac death for Patient II-2 is associated with
WDR62 mutations or an unrelated cardiac event. Of the mutations in
WDR62 reported thus far, approximately half have been frameshift mutations, as described here, distributed throughout the gene and predicted to result in premature truncation of the protein (Figure
1C).
At least ten genes have been associated with MCPH [
ASPM, MCPH1, WDR62, CDK5RAP2, CASC5, CENPJ, STIL, CEP135, CEP152 and
ZNF335] and are implicated in proliferation and migration of neuronal progenitors during embryonic cortical development [
19]. Clinical-radiological features have not been loci-specific and MCPH patients remain phenotypically indistinguishable [
13]. Thus, conventional molecular testing can be a long and expensive process and may not yield a diagnosis. Currently, sequential analysis of the eight clinically available MCPH genes would total more than $22,000 USD. Alternatively, eight of the ten MCPH genes could be sequenced as part of a microcephaly panel for $7,000 USD (
http://www.centogene.com accessed November 6
th, 2013, eight genes). Comparatively, WES would interrogate all ten microcephaly genes and is currently available in clinical laboratories at $5000 USD per patient, making it a cost-effective solution for rapid diagnosis in the clinic.